Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

Mindfulness During Accelerated TMS for Depression

Official title: MB-TBS: Mindfulness-Based Theta-Burst Stimulation-A Pilot Study Integrating Mindfulness Training Into Accelerated Neuromodulation Therapy for Depression

Run by Medical University of South Carolina · NCT07369557 · Data updated 2026-11-12

This pilot tests whether short guided mindfulness practice used during aiTBS treatment for major depressive disorder is feasible, acceptable, and shows early signals of benefit.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment20 (estimated)
SponsorMedical University of South Carolina
Academic / other
Locations2 sites (Charleston, South Carolina and 1 other locations)
StatusRecruiting
StartedApril 13, 2026
Main results expectedDecember 30, 2026
Study endsApril 30, 2027
Registry record updatedOctober 6, 2026
Trial IDNCT07369557 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with a clinical diagnosis of major depressive disorder who are already enrolled in an aiTBS course at MUSC and can use a smartphone or provided device.

Probably not a fit

Patients who do not engage with mindfulness practice or have contraindications to TMS or neuromodulation may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-arm pilot study embeds brief guided mindfulness practice through the Waking Up app during the inter-session intervals of an accelerated intermittent theta-burst stimulation course for major depressive disorder. Feasibility and acceptability are measured alongside changes in state mindfulness, hedonic tone, ease of meditation, and trait mindfulness over 4 and 12 weeks. Antidepressant response durability is explored with PHQ-9 assessments at 4 and 12 weeks. The study uses a study-created web app linked to the commercially available mindfulness app to deliver daily practice during aiTBS at MUSC. Enrollment requires eligibility for aiTBS, English proficiency, and access to a smartphone or provided device.

Why it matters

Potential benefit: If successful, the approach could offer an accessible way to enhance mood and sustain response during a TMS treatment course.

How similar studies have gone: Prior studies in related areas suggest that mindfulness components can be compatible with neuromodulation and may improve mood, but this exact embedding during aiTBS is exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinical diagnosis of MDD and eligible for aiTBS at MUSC
* Already enrolled in aiTBS course at MUSC
* English proficiency
* Smartphone or willingness to use study-provided device

Exclusion Criteria:

* TMS contraindications (e.g., seizure history, implants, pregnancy)
* Concurrent neuromodulation (ECT, VNS)
* Psychotic disorder, bipolar disorder, active substance use disorder, high suicide risk
* Unable/unwilling to engage in mindfulness or complete questionnaires

Where it's running

  • Iop
    Charleston, South Carolina, United States
    Recruiting
  • Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry
    Charleston, South Carolina, United States
    Not yet recruiting

Study contacts

  • Principal investigator: Clayton Olash, MD — Medical University of South Carolina

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.